Cargando…

Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial

PURPOSE: Microbiological diagnosis (MD) of infections remains insufficient. The resulting empirical antimicrobial therapy leads to multidrug resistance and inappropriate treatments. We therefore evaluated the cost-effectiveness of direct molecular detection of pathogens in blood for patients with se...

Descripción completa

Detalles Bibliográficos
Autores principales: Cambau, Emmanuelle, Durand-Zaleski, Isabelle, Bretagne, Stéphane, Brun-Buisson, Christian, Cordonnier, Catherine, Duval, Xavier, Herwegh, Stéphanie, Pottecher, Julien, Courcol, René, Bastuji-Garin, Sylvie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633620/
https://www.ncbi.nlm.nih.gov/pubmed/28374097
http://dx.doi.org/10.1007/s00134-017-4766-4
_version_ 1783269921951580160
author Cambau, Emmanuelle
Durand-Zaleski, Isabelle
Bretagne, Stéphane
Brun-Buisson, Christian
Cordonnier, Catherine
Duval, Xavier
Herwegh, Stéphanie
Pottecher, Julien
Courcol, René
Bastuji-Garin, Sylvie
author_facet Cambau, Emmanuelle
Durand-Zaleski, Isabelle
Bretagne, Stéphane
Brun-Buisson, Christian
Cordonnier, Catherine
Duval, Xavier
Herwegh, Stéphanie
Pottecher, Julien
Courcol, René
Bastuji-Garin, Sylvie
author_sort Cambau, Emmanuelle
collection PubMed
description PURPOSE: Microbiological diagnosis (MD) of infections remains insufficient. The resulting empirical antimicrobial therapy leads to multidrug resistance and inappropriate treatments. We therefore evaluated the cost-effectiveness of direct molecular detection of pathogens in blood for patients with severe sepsis (SES), febrile neutropenia (FN) and suspected infective endocarditis (SIE). METHODS: Patients were enrolled in a multicentre, open-label, cluster-randomised crossover trial conducted during two consecutive periods, randomly assigned as control period (CP; standard diagnostic workup) or intervention period (IP; additional testing with LightCycler(®)SeptiFast). Multilevel models used to account for clustering were stratified by clinical setting (SES, FN, SIE). RESULTS: A total of 1416 patients (907 SES, 440 FN, 69 SIE) were evaluated for the primary endpoint (rate of blood MD). For SES patients, the MD rate was higher during IP than during CP [42.6% (198/465) vs. 28.1% (125/442), odds ratio (OR) 1.89, 95% confidence interval (CI) 1.43–2.50; P < 0.001], with an absolute increase of 14.5% (95% CI 8.4–20.7). A trend towards an association was observed for SIE [35.4% (17/48) vs. 9.5% (2/21); OR 6.22 (0.98–39.6)], but not for FN [32.1% (70/218) vs. 30.2% (67/222), P = 0.66]. Overall, turn-around time was shorter during IP than during CP (22.9 vs. 49.5 h, P < 0.001) and hospital costs were similar (median, mean ± SD: IP €14,826, €18,118 ± 17,775; CP €17,828, €18,653 ± 15,966). Bootstrap analysis of the incremental cost-effectiveness ratio showed weak dominance of intervention in SES patients. CONCLUSION: Addition of molecular detection to standard care improves MD and thus efficiency of healthcare resource usage in patients with SES. ClinicalTrials.gov registration number: NCT00709358. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00134-017-4766-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5633620
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-56336202017-10-23 Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial Cambau, Emmanuelle Durand-Zaleski, Isabelle Bretagne, Stéphane Brun-Buisson, Christian Cordonnier, Catherine Duval, Xavier Herwegh, Stéphanie Pottecher, Julien Courcol, René Bastuji-Garin, Sylvie Intensive Care Med Original PURPOSE: Microbiological diagnosis (MD) of infections remains insufficient. The resulting empirical antimicrobial therapy leads to multidrug resistance and inappropriate treatments. We therefore evaluated the cost-effectiveness of direct molecular detection of pathogens in blood for patients with severe sepsis (SES), febrile neutropenia (FN) and suspected infective endocarditis (SIE). METHODS: Patients were enrolled in a multicentre, open-label, cluster-randomised crossover trial conducted during two consecutive periods, randomly assigned as control period (CP; standard diagnostic workup) or intervention period (IP; additional testing with LightCycler(®)SeptiFast). Multilevel models used to account for clustering were stratified by clinical setting (SES, FN, SIE). RESULTS: A total of 1416 patients (907 SES, 440 FN, 69 SIE) were evaluated for the primary endpoint (rate of blood MD). For SES patients, the MD rate was higher during IP than during CP [42.6% (198/465) vs. 28.1% (125/442), odds ratio (OR) 1.89, 95% confidence interval (CI) 1.43–2.50; P < 0.001], with an absolute increase of 14.5% (95% CI 8.4–20.7). A trend towards an association was observed for SIE [35.4% (17/48) vs. 9.5% (2/21); OR 6.22 (0.98–39.6)], but not for FN [32.1% (70/218) vs. 30.2% (67/222), P = 0.66]. Overall, turn-around time was shorter during IP than during CP (22.9 vs. 49.5 h, P < 0.001) and hospital costs were similar (median, mean ± SD: IP €14,826, €18,118 ± 17,775; CP €17,828, €18,653 ± 15,966). Bootstrap analysis of the incremental cost-effectiveness ratio showed weak dominance of intervention in SES patients. CONCLUSION: Addition of molecular detection to standard care improves MD and thus efficiency of healthcare resource usage in patients with SES. ClinicalTrials.gov registration number: NCT00709358. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00134-017-4766-4) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-04-03 2017 /pmc/articles/PMC5633620/ /pubmed/28374097 http://dx.doi.org/10.1007/s00134-017-4766-4 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original
Cambau, Emmanuelle
Durand-Zaleski, Isabelle
Bretagne, Stéphane
Brun-Buisson, Christian
Cordonnier, Catherine
Duval, Xavier
Herwegh, Stéphanie
Pottecher, Julien
Courcol, René
Bastuji-Garin, Sylvie
Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial
title Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial
title_full Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial
title_fullStr Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial
title_full_unstemmed Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial
title_short Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial
title_sort performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the evamica open-label, cluster-randomised, interventional crossover trial
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633620/
https://www.ncbi.nlm.nih.gov/pubmed/28374097
http://dx.doi.org/10.1007/s00134-017-4766-4
work_keys_str_mv AT cambauemmanuelle performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial
AT durandzaleskiisabelle performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial
AT bretagnestephane performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial
AT brunbuissonchristian performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial
AT cordonniercatherine performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial
AT duvalxavier performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial
AT herweghstephanie performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial
AT pottecherjulien performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial
AT courcolrene performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial
AT bastujigarinsylvie performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial
AT performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial